Jean Encarnacion
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,467, 4.2 times the $346 reported in 2021.
Across 207 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$828
- GSK$598
- Sanofi$502
- Regeneron Healthcare Solutions, Inc.$472
- Optinose US, Inc.$368
- Kaleo, Inc.$203
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,156100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 36 | $828 |
| GSK | 36 | $598 |
| Sanofi | 25 | $502 |
| Regeneron Healthcare Solutions, Inc. | 18 | $472 |
| Optinose US, Inc. | 28 | $368 |
| Kaleo, Inc. | 9 | $203 |
| Pharming Healthcare, Inc. | 6 | $162 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $133 |
| Blueprint Medicines Corporation | 4 | $114 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $110 |
| Novartis | 3 | $88 |
| Pfizer | 3 | $64 |
| Genentech USA, Inc. | 3 | $63 |
| Hikma Pharmaceuticals USA | 3 | $63 |
| Alk-abello, Inc | 3 | $49 |
| Galderma Laboratories, L.p. | 3 | $47 |
| Biocryst US Sales Co., LLC | 3 | $46 |
| Lilly USA, LLC | 2 | $46 |
| Organon | 4 | $27 |
| AbbVie | 1 | $27 |
| Viatris Specialty LLC | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| CSL Behring | 1 | $19 |
| Amgen | 1 | $19 |
| Grifols USA, LLC | 1 | $17 |
| Ionis Pharmaceuticals, Inc. | 1 | $16 |
| LEO Pharma Inc. | 1 | $14 |
How this compares
$4,156 in reported general payments places this provider in the 80th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine Hcl | 30 | $1,060 |
| Fluticasone Propionate | 23 | $464 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $278 |
| Montelukast Sodium | 22 | $203 |
| Levocetirizine Dihydrochloride | 18 | $190 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 18 | $147 |
| Azithromycin | 26 | $103 |
Paid to pharmacies, not to this prescriber.
Other medical in Katy
- Radha BernanderKaty$74K
- Chelsea BeiserKaty$18K
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Courtney AldridgeSan Antonio$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.